GeoVax Labs Inc (GOVX)

[3DYOGI]

Global Vaccine Market Surging to More Than $70 Billion by 2024

Investment Highlights

Recent entry into high-profile Zika vaccine space with multiple collaborators
Second generation Hemorrhagic Fever vaccine (Ebola, Marburg, Lassa) offering broad coverage and distinct advantages vs existing vaccines
Multiple targets in the Cancer Immunotherapy space
Most clinically advanced vaccine candidate for prevention of HIV infection in the developed world (HIV clade B – US, Western Europe
Novel vaccine technology developed at Emory University, NIH and CDC
Proven vaccine protection in HIV and Ebola animal models
Demonstrated human safety of MVA-VLP vaccine platform in hundreds of subjects to date
Equity capital leveraged with significant non-dilutive NIH support for clinical trials and research grants (>$50 million to date)
Strong global patent position with additional manufacturing technical know-how barriers to entry

#2 and # 22 on this list are now working at GOVX one is the scientific

Thomas P. Monath, MD, (Chairman) #2
Monathweb2Dr. Monath currently serves as Chief Scientific Officer and Chief Operating Officer of BioProtection Systems, a subsidiary of NewLink Genetics Corporation, where he is leading the development of an Ebola virus vaccine in partnership with Merck. Prior to joining NewLink, Dr. Monath held various industry roles at PaxVax Inc., Hookipa Biotech AG, Juvaris Inc., Xcellerex Inc., and Acambis Inc. prior to its acquisition by Sanofi Pasteur. In these roles, he led the development of a broad array of vaccines, including those against influenza, dengue, Japanese encephalitis, West Nile, yellow fever, cytomegalo, and smallpox viruses, as well as against Helicobacter pylori and Clostridium difficile; four of these are now licensed. He is a former partner of the Pandemic and Bio Defense Fund at Kleiner Perkins Caufield & Byers, a leading venture capital firm with a strong life sciences practice. He joined the biotechnology industry following a 20-year career at the U.S. Army Medical Research Institute of Infectious Diseases and the CDC’s Division of Vector-Borne Infectious Diseases. Dr. Monath received his undergraduate and medical degrees at Harvard, was awarded virology fellowships at the University of Ibadan in Ibadan, Nigeria, and at Massachusetts General Hospital in Boston, MA and completed residencies in medicine at Peter Bent Brigham Hospital in Boston. His published work includes over 400 papers and 6 books in the field of virology and vaccine developmen

--------------------------------------------------------------------------------------------------------
Farshad Guirakhoo, Ph.D., Chief Scientific Officer

Guirakhoo BW 2017Dr. Guirakhoo joined GeoVax as Senior Vice President of Research and Development in October 2015 and was promoted to Chief Scientific Officer in January 2017. Dr. Guirakhoo was named one of the ‘50 Most Influential People in Vaccines’ in Vaccine Nation’s 2014 list. His previous assignment was Chief Technology Officer at Vaxess Technologies, a Cambridge, MA, based biotechnology company researching thermostabilization of vaccines and biologics using silk fibroin protein. Prior to this, he served as Chief Scientific Officer at Hookipa Biotech in Vienna, Austria, developing vaccines against Cytomegalovirus and cancers based on a novel replication deficient viral vector platform. Prior to that, Dr. Guirakhoo held the position of Executive Director of External R&D at Sanofi Pasteur from 2007-20012. Before joining Sanofi Pasteur in 2007, Dr. Guirakhoo was Head of Virology Research at Acambis for 15 years. During this time, he co-invented the ChimeriVax™ technology platform in association with St. Louis University. This platform utilizes the YF 17D vaccine virus as a vector to develop chimeric live viruses. The ChimeriVax™ vector platform was successfully used in the development of innovative vaccines such as: a) a single dose vaccine against Japanese encephalitis (IMOJEV™), marketed in Asian countries by Sanofi, b) a single dose veterinary vaccine for the prevention of West Nile encephalitis (PREVNILE™), marketed by Merck Animal Health, and c) DENGVAXIA®, the world’s first dengue vaccine approved in Mexico and Brazil in December 2015 and marketed by Sanofi. This tetravalent vaccine represents a historic milestone for half of the world population who lives at risk of dengue. Dr. Guirakhoo has over 30 years of experience in developing vaccines against infectious diseases. Dr. Guirakhoo holds a BSc in Biology, a MSc in genetics, and a PhD in Virology from the Medical University of Vienna, Austria, and was awarded a National Research Council post-doctoral fellowship at the National Center for Disease Control and Prevention in Fort Collins, CO, from 1990-1992.

http://paxvax.com/sites/default/files/pdf/vaccinenation-2014-most-influential-people-in-vaccines.pdf

Look who is number one on the list? its Bill Gates GOVX now has #2 and #22

Sabby Management increased its holding from 3 Million in 2016 to 5,518,000 in 2017 over 10% owner

Emory University holds a 10% interest as well.

$GOVX